SYRE
Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$88.91
+1.90%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−36.9x
Market Cap
$7.84B
MomentumView details →
1D Return
+1.90%
YTD Return
+165.43%
RSI (14)
32.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−36.9x
Market Cap
$7.84B
RSI (14)
32.4
MomentumView details →
1D Return
+1.90%
YTD Return
+165.43%
SummaryUpdated Jun 1, 2026
Spyre Therapeutics, Inc. (NASDAQ:SYRE) is a preclinical-stage biotechnology company founded in 2013 and headquartered in Waltham, Massachusetts. The company went public in April 2016 and underwent a significant strategic transformation in November 2023, when it changed its name from Aeglea BioTherapeutics to Spyre Therapeutics to reflect its new focus on inflammatory bowel disease treatments. This pivot marked a complete shift from the company's previous focus on rare genetic diseases to developing novel antibody therapies for patients suffering from inflammatory bowel disease.
Similar companies
Latest newsMore news →
Spyre Therapeutics shares fell 12.35% in after-hours trading after its mid-stage clinical trial for a rheumatoid arthritis drug failed to meet internal criteria for advancing as a monotherapy.9d agoSpyre Therapeutics' Compensation Committee approved equity inducement awards of stock options for 19,436 shares and 6,186 restricted stock units to four non-executive employees on August 3, 2026, as material inducements to their employment acceptance.28d agoSpyre Therapeutics granted stock options and restricted stock units to six non-executive employees as inducement awards to accept employment.64d ago